Blurbs

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Guardant Health (GH) and BridgeBio Pharma (BBIO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intuitive Surgical (ISRGResearch Report), Guardant Health (GHResearch Report) and BridgeBio Pharma (BBIOResearch Report) with bullish sentiments.

Intuitive Surgical (ISRG)

J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Intuitive Surgical yesterday and set a price target of $280.00. The company’s shares closed last Thursday at $260.77.

According to TipRanks.com, Marcus is a 4-star analyst with an average return of 8.1% and a 52.6% success rate. Marcus covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Inspire Medical Systems, and Treace Medical Concepts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intuitive Surgical with a $250.25 average price target, implying a -3.2% downside from current levels. In a report issued on November 14, Truist Financial also maintained a Buy rating on the stock with a $300.00 price target.

See the top stocks recommended by analysts >>

Guardant Health (GH)

J.P. Morgan analyst Julia Qin maintained a Buy rating on Guardant Health yesterday and set a price target of $85.00. The company’s shares closed last Thursday at $48.41.

According to TipRanks.com, Qin is a 3-star analyst with an average return of 2.4% and a 50.0% success rate. Qin covers the Healthcare sector, focusing on stocks such as Singular Genomics Systems, Adaptive Biotechnologies, and Pacific Biosciences.

Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $79.58, representing a 63.3% upside. In a report issued on November 4, Citigroup also maintained a Buy rating on the stock with a $80.00 price target.

BridgeBio Pharma (BBIO)

J.P. Morgan analyst Anupam Rama maintained a Buy rating on BridgeBio Pharma yesterday and set a price target of $19.00. The company’s shares closed last Thursday at $9.65, close to its 52-week low of $4.98.

According to TipRanks.com, Rama is a 3-star analyst with an average return of 1.7% and a 44.2% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Springworks Therapeutics, and Apellis Pharmaceuticals.

Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $21.67, which is a 134.3% upside from current levels. In a report issued on November 7, Mizuho Securities also maintained a Buy rating on the stock with a $23.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ISRG:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More